TFF PHARMACEUTICALS INC TFFP 深 滬
交易中 09-20 12:37:08 美东时间
2.39
+0.080
+3.46%
華盛通- 最 高2.44
- 今 開2.35
- 成交量 1.03万股
- 最 低 2.25
- 昨 收 2.31
- 總市值 828.38万
- 52周最高 11.00
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 1.35
- 委 比 -80.69%
- 總股本 346.60万
- 歷史最高 528.50
- 量 比 0.31
- 振 幅 8.23%
- 歷史最低 1.35
- 每 手 1
- 風險率 2.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment
TFF Pharmaceuticals (NASDAQ:TFFP) shares jumped around 13% premarket on Wednesday after it entered a partnership with Emory University and the Biomedical Advanced Research and Development Authority (B...
09-11 19:28
快讯 | TFF Pharmaceuticals报告第二季度财务业绩并提供公司更新
TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corpo...
08-15 04:05
快讯 | TFF Pharmaceuticals Q2净利润美元指数-450万
TFF Pharmaceuticals Q2 Net Income USD -4.5 Million
08-15 04:05
快讯 | tff pharmaceuticals：使用tff tac治疗后，观察到异常表达的拒绝相关基因集数量减少了6.5倍。
TFF Pharmaceuticals: Observed 6.5-Fold Reduction in Number of Abnormally Expres...
08-06 20:04
快讯 | TFF Pharmaceuticals公司：TFF Tac约占口服他克莫司剂量的20％，可预防急性排斥反应并达到之前口服药物的80％峰谷血药浓度。
TFF Pharmaceuticals Inc: TFF Tac at About 20% of Oral Tacrolimus Dose Prevented...
08-06 20:03
快讯 | tff pharmaceuticals：TFF Tac治疗后无供体特异性抗体（DSA）产生
TFF Pharmaceuticals: No Production of Donor-Specific Antibodies (Dsa) After Tre...
08-06 20:03
快讯 | TFF Pharmaceuticals提供TFF Tac（他克莫司吸入粉末）第2期试验的持续正面结果，以预防肺移植排斥症。
TFF Pharmaceuticals Provides Continued Positive Outcomes From Tacrolimus Inhala...
08-06 20:00
快讯 | tff pharmaceuticals聘请Outcome Capital作为战略顾问，以评估合作和授权机会
TFF Pharmaceuticals Engages Outcome Capital as a Strategic Advisor for Evaluati...
06-26 19:00
快讯 | TFF Pharmaceuticals:基于FDA的反馈，预计TFF Tac的临床推进时间表或估算成本不会有变化。
TFF Pharmaceuticals: Based on FDA Feedback, Does Not Expect Change to Timelines...
06-24 19:06
